PE20040835A1 - Administracion combinada de una indolina con un agente quimioterapeutico para transtornos de proliferacion celular - Google Patents
Administracion combinada de una indolina con un agente quimioterapeutico para transtornos de proliferacion celularInfo
- Publication number
- PE20040835A1 PE20040835A1 PE2003001154A PE2003001154A PE20040835A1 PE 20040835 A1 PE20040835 A1 PE 20040835A1 PE 2003001154 A PE2003001154 A PE 2003001154A PE 2003001154 A PE2003001154 A PE 2003001154A PE 20040835 A1 PE20040835 A1 PE 20040835A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- formula
- inhibitors
- chemotherapeutic agent
- antireversible
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1
- 108010002164 tyrosine receptor Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Abstract
SE REFIERE AL USO COMBINADO DE UN COMPUESTO DE FORMULA I Y POR LO MENOS UN AGENTE QUIMIOTERAPEUTICO; EN DONDE, PARA LA FORMULA I INCLUYENDO SUS SALES, HIDRATOS O SOLVATOS ACEPTABLES PARA USO FARMACEUTICO, CADA R ES H, HIDROXI, ALQUILO, ARILO, CICLOALQUILO, ENTRE OTROS; CADA R1 ES ALQUILO, HALO, ALCOXI, HALOALQUILO, ENTRE OTROS; CADA R2 ES ALQUILO, ARILO, HETEROARILO, ENTRE OTROS; CADA R5 ES H, ALQUILO, ARILO, HALOALQUILO, CICLOALQUILO, ENTRE OTROS; X ES O o S; p ES 0, 1, 2 o 3; q ES 0, 1 o 2; Z ES HIDROXI, O-ALQUILO, ENTRE OTROS. Y DICHO AGENTE QUIMIOTERAPEUTICO ES SELECCIONADO DEL GRUPO FORMADO POR AGENTES DE INTERFERENCIA DE MICROTUBULOS, INHIBIDORES DE TOPOISOMERASA, AGENTES DE ALQUILACION, INHIBIDORES DE TIMIDILATO SINTASA, ACTIVADORES ESTERORIDALES IRREVERSIBLES DE AROMATASA, ANTI-METABOLITOS, ANTAGONISTAS DE PIRIMIDINA, ANTAGONISTAS DE PURINA, INHIBIDORES DE LA REDUCTASA RIBONUCLEOTIDICA E INHIBIDORES DE QUINASA. SON COMPUESTOS PREFERIDOS PARA LA FORMULA I: (2-DIMETILAMINO-ETIL)-AMIDA DEL ACIDO 5-(5-FLUORO-2-OXO-1,2-DIHIDRO-INDOL-3-ILIDENMETIL)-2,4-DIMETIL-1H-PIRROL-3-CARBOXILICO; (2-PIRROLIDIN-1-IL-ETIL)-AMIDA DEL ACIDO 5-(5-FLUORO-2-OXO-1,2-DIHIDRO-INDOL-3-ILIDENMETIL)-2,4-DIMETIL-1H-PIRROL-3-CARBOXILICO; ENTRE OTROS. LOS COMPUESTOS DE FORMULA I SON INHIBIDORES DEL RECEPTOR DE QUINASA TIROSINA (RTK) Y EN COMBINACION CON UN AGENTE QUIMIOTERAPEUTICO SON UTILES PARA TRATAR TRASTORNOS DE PROLIFERACION CELULAR COMO EL CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42638602P | 2002-11-15 | 2002-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040835A1 true PE20040835A1 (es) | 2004-11-18 |
Family
ID=32326343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003001154A PE20040835A1 (es) | 2002-11-15 | 2003-11-14 | Administracion combinada de una indolina con un agente quimioterapeutico para transtornos de proliferacion celular |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040152759A1 (es) |
| EP (1) | EP1562600A4 (es) |
| JP (1) | JP2006508981A (es) |
| KR (1) | KR20050086594A (es) |
| CN (2) | CN100430060C (es) |
| AR (1) | AR042042A1 (es) |
| AU (1) | AU2003290943A1 (es) |
| BR (1) | BR0315630A (es) |
| CA (1) | CA2506308A1 (es) |
| CO (1) | CO5700778A2 (es) |
| GT (1) | GT200300245A (es) |
| MX (1) | MXPA05005150A (es) |
| NL (1) | NL1024779C2 (es) |
| NO (1) | NO20052578L (es) |
| PA (1) | PA8588601A1 (es) |
| PE (1) | PE20040835A1 (es) |
| PL (1) | PL376954A1 (es) |
| RU (1) | RU2342140C2 (es) |
| TW (1) | TW200418837A (es) |
| UY (1) | UY28081A1 (es) |
| WO (1) | WO2004045523A2 (es) |
| ZA (1) | ZA200503841B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| US7994159B2 (en) * | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| AU2005333515B2 (en) * | 2004-07-09 | 2012-05-10 | Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
| EP1863532A1 (en) * | 2005-03-23 | 2007-12-12 | Pfizer Products Incorporated | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| AU2006245421A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
| ATE457727T1 (de) * | 2005-06-03 | 2010-03-15 | Novartis Ag | Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen |
| EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| EP1938842A4 (en) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS |
| US8361996B2 (en) * | 2005-09-15 | 2013-01-29 | Council Of Scientific And Industrial Research | Imidazolyl substituted steroidal and indan-1-one derivatives |
| BRPI0616202A2 (pt) * | 2005-09-20 | 2011-06-14 | Pfizer Prod Inc | formas de dosagem e uso de um inibidor da tirosina quinase |
| AU2006309551B2 (en) * | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
| ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
| DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途 |
| CN101511793B (zh) * | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| WO2009094216A1 (en) * | 2008-01-22 | 2009-07-30 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| JP5399926B2 (ja) * | 2008-01-29 | 2014-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管阻害物質とタキサンとの併用 |
| JP2011526615A (ja) * | 2008-07-02 | 2011-10-13 | ジェネリクス・（ユーケー）・リミテッド | ３−ピロール置換２−インドリノン誘導体の調製 |
| US20100143295A1 (en) * | 2008-12-05 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Quinazoline inhibitors of egfr tyrosine kinase |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| RU2580609C2 (ru) | 2011-04-18 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
| WO2013152193A2 (en) * | 2012-04-04 | 2013-10-10 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| WO2014185540A1 (en) | 2013-05-14 | 2014-11-20 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| KR20250024102A (ko) | 2015-02-25 | 2025-02-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| US10526288B2 (en) * | 2016-06-09 | 2020-01-07 | Yuki Gosei Kogyo Co., Ltd. | Method for preparing 4-(piperidin-4-yl)morpholine |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US20200197384A1 (en) | 2017-05-16 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CN114585389A (zh) * | 2019-09-26 | 2022-06-03 | 星法马私人有限公司 | 治疗性树枝状大分子 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08503450A (ja) * | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド） |
| TR200003514T2 (tr) * | 1998-05-29 | 2002-05-21 | Sugen Inc. | Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri |
| PT1233943E (pt) * | 1999-11-24 | 2011-09-01 | Sugen Inc | Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres |
| MXPA02006263A (es) * | 1999-12-22 | 2004-02-26 | Sugen Inc | Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona. |
| BRPI0117360B8 (pt) * | 2000-02-15 | 2021-07-06 | Upjohn Co | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
| MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
-
2003
- 2003-11-13 AR ARP030104194A patent/AR042042A1/es unknown
- 2003-11-14 US US10/712,296 patent/US20040152759A1/en not_active Abandoned
- 2003-11-14 PE PE2003001154A patent/PE20040835A1/es not_active Application Discontinuation
- 2003-11-14 PL PL376954A patent/PL376954A1/pl not_active Application Discontinuation
- 2003-11-14 TW TW092132030A patent/TW200418837A/zh unknown
- 2003-11-14 JP JP2004553729A patent/JP2006508981A/ja not_active Withdrawn
- 2003-11-14 AU AU2003290943A patent/AU2003290943A1/en not_active Abandoned
- 2003-11-14 KR KR1020057008541A patent/KR20050086594A/ko not_active Ceased
- 2003-11-14 CA CA002506308A patent/CA2506308A1/en not_active Abandoned
- 2003-11-14 PA PA20038588601A patent/PA8588601A1/es unknown
- 2003-11-14 CN CNB200380103225XA patent/CN100430060C/zh not_active Expired - Fee Related
- 2003-11-14 NL NL1024779A patent/NL1024779C2/nl not_active IP Right Cessation
- 2003-11-14 MX MXPA05005150A patent/MXPA05005150A/es unknown
- 2003-11-14 BR BR0315630-3A patent/BR0315630A/pt not_active IP Right Cessation
- 2003-11-14 GT GT200300245A patent/GT200300245A/es unknown
- 2003-11-14 WO PCT/US2003/036526 patent/WO2004045523A2/en not_active Ceased
- 2003-11-14 UY UY28081A patent/UY28081A1/es not_active Application Discontinuation
- 2003-11-14 CN CNA2008100814220A patent/CN101259131A/zh active Pending
- 2003-11-14 EP EP03783527A patent/EP1562600A4/en not_active Withdrawn
- 2003-11-14 RU RU2005118417/14A patent/RU2342140C2/ru not_active IP Right Cessation
-
2005
- 2005-05-11 CO CO05045078A patent/CO5700778A2/es not_active Application Discontinuation
- 2005-05-12 ZA ZA200503841A patent/ZA200503841B/en unknown
- 2005-05-27 NO NO20052578A patent/NO20052578L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NL1024779C2 (nl) | 2004-11-09 |
| WO2004045523A2 (en) | 2004-06-03 |
| GT200300245A (es) | 2004-06-23 |
| CO5700778A2 (es) | 2006-11-30 |
| CA2506308A1 (en) | 2004-06-03 |
| NL1024779A1 (nl) | 2004-05-18 |
| NO20052578L (no) | 2005-05-27 |
| CN101259131A (zh) | 2008-09-10 |
| RU2342140C2 (ru) | 2008-12-27 |
| UY28081A1 (es) | 2004-06-30 |
| PL376954A1 (pl) | 2006-01-09 |
| EP1562600A2 (en) | 2005-08-17 |
| TW200418837A (en) | 2004-10-01 |
| RU2005118417A (ru) | 2006-01-20 |
| MXPA05005150A (es) | 2005-07-22 |
| KR20050086594A (ko) | 2005-08-30 |
| CN1711089A (zh) | 2005-12-21 |
| US20040152759A1 (en) | 2004-08-05 |
| BR0315630A (pt) | 2005-08-23 |
| JP2006508981A (ja) | 2006-03-16 |
| AR042042A1 (es) | 2005-06-08 |
| PA8588601A1 (es) | 2004-05-21 |
| AU2003290943A1 (en) | 2004-06-15 |
| WO2004045523A3 (en) | 2004-09-30 |
| ZA200503841B (en) | 2006-09-27 |
| EP1562600A4 (en) | 2008-06-25 |
| CN100430060C (zh) | 2008-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040835A1 (es) | Administracion combinada de una indolina con un agente quimioterapeutico para transtornos de proliferacion celular | |
| ES2942310T3 (es) | Inhibidores aza-heterobicíclicos de MAT2A y métodos de uso para el tratamiento del cáncer | |
| ES2886887T3 (es) | Inhibidor de EGFR y preparación y aplicación del mismo | |
| Lu et al. | Concise copper-catalyzed one-pot tandem synthesis of benzimidazo [1, 2-b] isoquinolin-11-one derivatives | |
| CO6190611A2 (es) | Derivados de espirocromanona sustituidos | |
| PE20011334A1 (es) | Compuestos y composiciones de indazol de formula (i) | |
| CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
| CO5540312A2 (es) | Derivados de imidazo 1,2-a-piridina para la profilaxis y el tratamiento de infecciones virales por herpes | |
| PE20020469A1 (es) | Policiclicos nucleotidicos como inhibidores de xantina fosfodiesterasa v | |
| AR035456A1 (es) | Compuestos derivados de dihidro-benzo[b][1,4]-diazepin-2-ona , su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| ECSP088145A (es) | Derivados bicíclicos como inhibidores de la cinasa p38 | |
| PE20011259A1 (es) | Derivado de piridina y pirimidina | |
| CO5700742A2 (es) | Moduladores del receptor de quimioquina ccr5 | |
| AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| BRPI0714663A2 (pt) | composto e composiÇÕes como moduladores da via hedgehog | |
| HRP20050496A2 (en) | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| CR8530A (es) | Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos | |
| TW200732329A (en) | Aryl-isoxazolo-4-yl-oxadiazole derivatives | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| AR056888A1 (es) | Derivados de heterociclil imidazol | |
| CO5601021A2 (es) | Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb | |
| AR037096A1 (es) | Compuestos de benzimidazol sustituido,composicion farmacologica que los comprende y uso de los mismos para la preparacion de una droga | |
| PE20050162A1 (es) | Derivados de imidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |